Prescription medicine
Vusolimogene oderparepvec Brand names: Tudriqev
Vusolimogene oderparepvec (Tudriqev) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the vusolimogene oderparepvec FDA label on DailyMed (effective September 1, 2026); every vusolimogene oderparepvec label on DailyMed.
Highlights of the record
FDA label of September 1, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageTUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
Forms and strengths
Injection (suspension).
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
What is vusolimogene oderparepvec used for?
From the label: indications and usageTUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response [ see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). […]
Source: FDA drug label (Tudriqev), Replimune, Inc., effective September 1, 2026 (SPL set 26627b8d-91ac-4f76-a213-7e25efd024d1), via openFDA; the full label on DailyMed
Is there a generic for vusolimogene oderparepvec (Tudriqev)?
No generic vusolimogene oderparepvec is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the vusolimogene oderparepvec label say about other medicines?
The vusolimogene oderparepvec label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Nivolumab | warnings and precautions | TUDRIQEV in combination with nivolumab may result in immune-mediated events. |
Source: FDA drug label (Tudriqev), Replimune, Inc., effective September 1, 2026 (SPL set 26627b8d-91ac-4f76-a213-7e25efd024d1), via openFDA; the full label on DailyMed
What next?
- Check an interaction
- what two or more labels say about each other